We are live on ! Find out more
TERN

Terns Pharmaceuticals
TERN

Delisted

TERN was delisted on the 4th of May, 2026.

Back to rankings

44 hedge funds and large institutions have $50M invested in Terns Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

350% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 2

19% more funds holding

Funds holding: 37 → 44 (+7)

0.95% more ownership

Funds ownership: 65.67% → 66.63% (+0.95%)

29% less repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 14

57% less capital invested

Capital invested by funds: $117M → $50M (-$66.7M)

Holders
44
Holders Change
+7
Holders Change %
+18.92%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
10
Reduced
14
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Antara Capital
New York
+$534K
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$523K
3
Renaissance Technologies
Renaissance Technologies
New York
+$289K
4
Millennium Management
Millennium Management
New York
+$150K
5
DCM
Driehaus Capital Management
Illinois
+$150K

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$2.05M
2
Vanguard Group
Vanguard Group
Pennsylvania
-$535K
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$390K
4
Morgan Stanley
Morgan Stanley
New York
-$346K
5
BCM
Bridgeway Capital Management
Texas
-$140K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$11.3M – – –
VC
2
Vivo Capital
California
$7.95M – – –
DM
3
Deerfield Management
New York
$6.97M – – –
Fidelity Investments
4
Fidelity Investments
Massachusetts
$6.89M -$2.05M -479,527 -17%
SCM
5
Suvretta Capital Management
New York
$3.68M – – –
AC
6
Antara Capital
New York
$3.19M +$534K +125,000 +13%
BlackRock
7
BlackRock
New York
$2.19M -$36.7K -8,594 -1%
DCMIC
8
Decheng Capital Management III (Cayman)
Cayman Islands
$2.12M +$3.05M +714,285 New
Vanguard Group
9
Vanguard Group
Pennsylvania
$1.29M -$535K -125,308 -22%
SB
10
Samsara BioCapital
California
$859K – – –
Geode Capital Management
11
Geode Capital Management
Massachusetts
$532K -$6.93K -1,624 -0.9%
State Street
12
State Street
Massachusetts
$485K +$5.2K +1,218 +0.8%
Point72 Asset Management
13
Point72 Asset Management
Connecticut
$364K +$523K +122,573 New
Northern Trust
14
Northern Trust
Illinois
$311K -$30.8K -7,214 -6%
Millennium Management
15
Millennium Management
New York
$263K +$150K +35,229 +66%
CCM
16
CAAS Capital Management
New York
$255K – – –
CAC
17
Cowen and Company
New York
$252K – – –
Renaissance Technologies
18
Renaissance Technologies
New York
$201K +$289K +67,800 New
BCM
19
Bridgeway Capital Management
Texas
$186K -$140K -32,800 -34%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$112K +$10.1K +2,359 +7%
DCM
21
Driehaus Capital Management
Illinois
$104K +$150K +35,100 New
Charles Schwab
22
Charles Schwab
California
$86K – – –
MAM
23
Marquette Asset Management
Minnesota
$65K +$22.1K +5,183 +31%
PPA
24
Parametric Portfolio Associates
Washington
$62K +$36.1K +8,467 +69%
Goldman Sachs
25
Goldman Sachs
New York
$49K +$5.2K +1,219 +8%
1
2

TERN Hedge Fund Activity: Q1 2022 in Review

44 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Terns Pharmaceuticals (TERN) for Q1 2022, worth a combined $50M — down 57% from $117M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new TERN positions and 2 closed out — a net gain of 7 holders — while 10 added to existing stakes and 14 trimmed.

The largest buyer was Antara Capital, adding an estimated $534K. The largest seller was Fidelity Investments, cutting an estimated $2.05M.

  • 44 institutional investors held Terns Pharmaceuticals (TERN) as of Q1 2022, up from 37 in Q4 2021.
  • Funds reported $50M of Terns Pharmaceuticals stock for Q1 2022, down 57% quarter-over-quarter.
  • 9 funds opened new Terns Pharmaceuticals positions in Q1 2022 and 2 closed out, a net change of +7 holders.
  • The largest Terns Pharmaceuticals buyer in Q1 2022 was Antara Capital, an estimated $534K added.
  • The largest Terns Pharmaceuticals seller in Q1 2022 was Fidelity Investments, an estimated $2.05M sold.

Based on aggregated 13F filings for Q1 2022.